title: Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.
abstract: Adherent cells from HIV-infected subjects as well as in vitro HIV-infected normal adherent cells produce spontaneously a 29-kD (p29) factor that inhibits mitogen-induced proliferation of normal T cells. p29 mediates a partial dose-dependent inhibition of total protein synthesis in both nonstimulated and PHA-activated cells that is associated with impaired PHA-induced expression of IL-2 receptor (IL-2R)alpha chain, HLA-class II molecules, and production of IL-2 by these cells; conversely, p29 does not modify the expression of IL-2R beta chain, 4F2, CD9, or transferrin receptor, or the production of IL-1 and TNF alpha by the cells. 1 h preincubation of the cells with p29 is sufficient to detect its biologic activity and added rIL-2 abrogates p29-induced inhibition of IL-2R alpha chain expression; however, p29 does not display any biologic effect on already expressed IL-2R alpha chains. The impaired expression of IL-2R alpha chain mediated by p29 is not due to a decreased accumulation of the corresponding mRNA transcripts, but is associated with a two-fold increase of intracellular cAMP. Binding experiments with 125I-rIL-2 reveals that p29 induces a 50% decrease in the number of both high and low affinity IL-2R per cell. p29 also inhibits alloantigen-induced proliferation of PBMC, whereas it does not modify IL-2-dependent proliferation of 48-h PHA-blasts that already express high affinity IL-2R. These findings indicate that p29 mediates its biologic activity during early stages of T cell activation affecting the expression of high affinity IL-2R and production of IL-2, through a nontranscriptional mechanism involving an increase of intracellular cAMP.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.
authors.forename: A
authors.initials: A
authors.lastname: Ammar
authors.forename: Y
authors.initials: Y
authors.lastname: Sahraoui
authors.forename: A
authors.initials: A
authors.lastname: Tsapis
authors.forename: A M
authors.initials: AM
authors.lastname: Bertoli
authors.forename: C
authors.initials: C
authors.lastname: Jasmin
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
mesh_terms: D000242:Cyclic AMP / Q000378:metabolism; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects*; D014176:Protein Biosynthesis; D011506:Proteins / Q000494:pharmacology*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*; D012191:Retroviridae Proteins / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: C075749:HIV-infected adherent cell-derived inhibitory factor, p29; D007376:Interleukin-2; D011506:Proteins; D015375:Receptors, Interleukin-2; D012191:Retroviridae Proteins; D000242:Cyclic AMP